Hemorrhagic cystitis (HC) is a frequent and sometimes life-threatening complication after hematopoietic SCT (HSCT). Many therapeutic approaches have been performed to control HC, but their effect is ...
Hemorrhagic cystitis (HC) is a well-recognized complication of hematopoietic stem cell transplantation (HSCT) in children and adolescents. The etiology is often multi-factorial and includes ...
PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the ...
Please provide your email address to receive an email when new articles are posted on . BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to posoleucel for the treatment of virus-associated hemorrhagic cystitis ...
Phase 3 registrational study of posoleucel in virus-associated hemorrhagic cystitis is ongoing An inflammatory disease of the bladder, virus-associated HC is a serious complication of hematopoietic ...
BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, ...
(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...
I encountered my most memorable patient while working as a urology nurse practitioner at a large urban hospital. The patient was 70 years old, alert and oriented and lived in a nursing home. He had a ...
Pelvic Cancer Induced Hemorrhagic Cystitis Market · GlobeNewswire Inc. The pelvic cancer induced hemorrhagic cystitis market size has experienced robust growth recently, increasing from $3.1 billion ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results